Every wet-lab experiment costs something real: reagents, animal or tissue subjects, weeks of a researcher's time, and — if the hypothesis turns out to be wrong — all of it spent to learn what didn't work. Multiply that by the number of plausible hypotheses in a complex signaling network, and the honest bottleneck in biological research usually isn't imagination. It's throughput.

In silico — literally, "in silicon" — is the term for running that first pass of testing inside a computational model instead of a physical one. It doesn't replace the lab. It changes what gets to the lab in the first place, by filtering a large space of plausible ideas down to the handful worth spending real material and real time on.

What a model can and can't tell you

A good computational model of a biological system isn't a prediction of certainty — it's a ranking of plausibility, built from the evidence that already exists. Feed it a densely connected map of how signals relate to each other, and it can surface which downstream effect is most consistent with the upstream evidence, which candidate relationships contradict each other, and where the evidence is simply too thin to trust yet.

That last part matters as much as the first two. A model that can say "we don't know enough here" is more useful than one that produces a confident answer regardless of how much evidence actually supports it. Distinguishing a well-supported hypothesis from a merely plausible one — and being honest about which is which — is the actual job.

Why this is the core of ASAP

Our platform, ASAP, is built around exactly this discipline: represent what's known as a structured, evidence-weighted graph rather than a flat list, then use that structure to prioritize which next experiment would actually be informative — the one most likely to confirm or falsify something that matters, not just the one that's easiest to run. Every relationship the model surfaces is meant to be traceable back to the evidence that supports it, so a researcher reviewing its output can see the reasoning, not just the conclusion.

None of this replaces experimental validation — it never should. What it changes is the ratio of validated hypotheses to failed ones a research program can produce with the same budget, by making sure the ideas that reach the bench were the ones most worth testing in the first place.

This article describes a general research methodology and Instructional Biology's platform approach. It is not a claim of clinical efficacy for any Instructional Biology product. Instructional Biology's platform and programs are research-stage and have not completed clinical development.
← Back to Insights